Answers are grounded in this paper and cite their sources.
Esophageal cancer (EC) is among the most prevalent and lethal malignancies worldwide, particularly in China where esophageal squamous cell carcinoma (ESCC) represents the predominant histological subtype. Systemic chemotherapy plus immunotherapy remains the standard first-line treatment for advanced or metastatic ESCC; however, chemotherapy-associated toxicities frequently impair quality of life and limit treatment adherence. Human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in gastroesophageal junction (GEJ) adenocarcinoma, with multiple anti-HER2 agents approved globally. In contrast, HER2 overexpression is rare in ESCC, and its clinical significance and optimal treatment strategy remain poorly defined, especially in patients with extensive metastatic disease. Herein, we describe a 53-year-old male patient diagnosed with HER2-positive advanced ESCC complicated by diffuse liver metastases who achieved durable response following administration of a chemotherapy-free regimen combined with anti-HER2 therapy. Notably, the patient obtained durable disease control without traditional chemotherapy, supporting the feasibility and potential benefit of chemotherapy-free anti-HER2-based strategies in this rare molecular subset. This case provides valuable real-world evidence for the clinical utility of HER2-directed therapy in HER2-positive ESCC, even in the setting of diffuse liver metastases, and highlights the potential of chemotherapy-free approaches to improve outcomes and quality of life. Further clinical investigations are warranted to validate this promising therapeutic strategy.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: